1. Home
  2. HBB vs ACRS Comparison

HBB vs ACRS Comparison

Compare HBB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

N/A

Current Price

$16.45

Market Cap

210.8M

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.26

Market Cap

230.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
ACRS
Founded
1904
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.8M
230.8M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
HBB
ACRS
Price
$16.45
$3.26
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.75
AVG Volume (30 Days)
21.5K
1.3M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
2.91%
N/A
EPS Growth
24.53
N/A
EPS
2.34
N/A
Revenue
$607,430,000.00
$15,742,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6.06
P/E Ratio
$7.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$1.05
52 Week High
$21.20
$3.57

Technical Indicators

Market Signals
Indicator
HBB
ACRS
Relative Strength Index (RSI) 63.35 66.07
Support Level $15.24 $3.12
Resistance Level $16.85 $3.48
Average True Range (ATR) 0.69 0.22
MACD 0.10 0.05
Stochastic Oscillator 86.26 79.80

Price Performance

Historical Comparison
HBB
ACRS

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: